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Stem cell factor plays a key role in the development of
human mast cells via interaction with Kit receptor.We
and other groups have previously shown that a number
of cytokines can regulate the stem-cell-factor-depen-
dent development of mast cells in vitro. In this study
we investigated the e¡ect of retinoic acid on human
mast cells in vitro and in vivo. Retinoids are known
to have strong modulatory e¡ects on hematopoietic
di¡erentiation. We found that all-trans-retinoic acid, at
concentrations as low as 1 nM, inhibits the stem-
cell-factor-dependent di¡erentiation of mast cells in vi-
tro. This e¡ect of retinoic acid was found to be on pro-
genitor cells, whereas more mature mast cells were less
a¡ected. The use of speci¢c agonists binding either to
the RAR or the RXR nuclear receptors indicated in-
volvement of both the RAR/RXR and RXR/RXR
pathways in inhibiting mast cell di¡erentiation. In con-
trast to the e¡ects on mast cell progenitors, retinoic acid
had no e¡ect on the number of mature mast cells in
skin organ cultures. Furthermore, topical treatment of
normal skin with a retinoic-acid-containing cream
caused an increase in the number of tryptase-positive
mast cells, whereas the numbers of the major cutaneous
mast cell type, tryptase- and chymase-positive mast
cells, remained una¡ected. Our results suggest that reti-
noic acid suppresses commitment of progenitor cells
into the mast cell lineage and/or acts on early mast
cell progenitors, whereas mature cutaneous mast cells
are less susceptible to retinoic acid. Key words: di¡e-
rentiation/hematopoiesis/stem cell factor/tryptase. J Invest
Dermatol 120:239 ^245, 2003
H
uman mast cells, which in their mature form nor-
mally can only be found within the tissue, originate
from bone-marrow-derived, circulating CD34þ
progenitor cells (Kirshenbaum et al, 1991; F˛dinger
et al, 1994). The lineage speci¢city of mast cells and
their relationship to other hematopoietic cells are still not fully
understood, however. Stem cell factor (SCF), the ligand for Kit,
is the most important stimulatory cytokine for human mast cells,
inducing the growth and di¡erentiation of mast cells in vitro and
in vivo (Irani et al, 1992; Valent et al, 1992; Mitsui et al, 1993; Costa
et al, 1996). Other cytokines have been shown to in£uence this
process, either by promoting [interleukin-6 (IL-6) and thrombo-
poietin] (Saito et al, 1996; Sawai et al, 1999), or by inhibiting [IL-3,
IL-4, IL-13, interferon-g, and granulocyte-macrophage colony
stimulating factor (GM-CSF)] (Nilsson et al, 1994b; Sillaber et al,
1994; Nilsson and Nilsson, 1995; Du et al, 1997; Kirshenbaum et al,
1998; Hjertson et al, 1999) mast cell development. Some data indi-
cate that uncommitted progenitors and mast cell progenitors have
an enhanced susceptibility to inhibitory stimulus compared to
more mature cells of the mast cell lineage. For instance, if the
administration of GM-CSF is delayed for 1^3 wk, the mast cell
development is less a¡ected (Du et al, 1997).
Retinoic acid (RA), the natural acidic derivative of vitamin
A (retinol), has been demonstrated to have strong modulatory
e¡ects on the growth and di¡erentiation of di¡erent types of
cells, including epithelial and hematopoietic cells (Lotan, 1980;
Douer and Koe¥er, 1982; Nagler et al, 1986).Therefore we decided
to study its possible e¡ects on mast cell development in vitro and
in vivo. There are several isoforms of RA, including all-trans-RA
(atRA) and 9-cis-RA (9cisRA). The retinoids have been shown
to exert their actions by binding to nuclear receptors, which
function as dimers (Giguere et al, 1987; Petkovich et al, 1987;
Mangelsdorf et al, 1990) that bind to response elements in the
DNA (Zhang et al, 1992). RA has two receptors, RAR and
RXR, which form RAR/RXR and RXR/RXR comple-
xes. RXR can also form heterodimers with orphan receptors
(Mangelsdorf and Evans, 1995). Both atRA and 9cisRA activate
RAR, whereas RXR only binds 9cisRA.
In this study we have investigated the e¡ects of RA on human
mast cells in vitro and in vivo. The results show that RA has a pro-
nounced negative e¡ect on the SCF-dependent development of
mast cells from cord blood mononuclear cells (CBMNC), and
that this inhibition re£ects an interference of RA with the SCF
stimulation of progenitor cells. In contrast, RA had no apparent
e¡ect on the number and Kit expression of mature tryptase- and
chymase-positive mast cells (MCTC) in human skin tissue.
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MATERIALS AND METHODS
Primary cell cultures Mononuclear cells were separated from
heparinized human umbilical cord blood by Ficoll-Paque (Amersham
Pharmacia Biotech, Uppsala, Sweden) gradient centrifugation. The cells
were washed twice in phosphate-bu¡ered saline (PBS) and resuspended in
RPMI 1640 medium supplemented with 10% fetal bovine serum, 50 mM
2-mercaptoethanol, 10 mM HEPES, 2 mM L-glutamine, 0.1 mM
nonessential amino acids, 100 IU per ml penicillin, and 50 mg per ml
streptomycin (Life Technologies, Renfrewshire, U.K.). The cells were
seeded at a density of 1106 cells in 1 ml in 24-well plates (Costar,
Cambridge, MA) and grown for 2, 4, or 6 wk with the addition of
di¡erent combinations of retinoids and SCF. Recombinant human SCF
(rhSCF) (Immunex, Seattle,WA) was used at 50 ng per ml, atRA (Sigma,
St. Louis, MO) and 9cisRA (Sigma) at 1^1000 nM. The agonists TTNPB
and SR11237 (Lehmann et al, 1992) were used at 100 nM and 1000 nM,
respectively. The solvents (dimethylsulfoxide and ethanol) did not a¡ect
the di¡erentiation of CBMNC. Half of the medium was replaced twice
a week. At the time of processing the cultures, both adherent cells and
cells in suspension were collected. The cell number and viability were
determined by trypan blue exclusion.
Cytocentrifuge preparations of cultured CBMNC were subjected to
immunohistochemical labeling for mast cell tryptase using the G3
monoclonal antibody (2 mg per ml) (provided by Dr. L.B. Schwartz,
MCV, Richmond, VA) as described by Irani et al (1989). Brie£y, the slides
were incubated with the primary antibody overnight at 41C, followed by
APAAP labeling (Dakopatts, Olvsj ,˛ Sweden) and counterstaining with
Mayer’s hematoxylin before the slides were mounted.
Cell line cultures The human mast cell line HMC-1 (provided by Dr.
J.H. Butter¢eld, Mayo Clinic, Rochester, MN) (Butter¢eld et al, 1988;
Nilsson et al, 1994a) was cultured in Iscove’s modi¢ed Dulbecco’s medium
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU
per ml penicillin, 50 mg per ml streptomycin (Life Technologies), and
1.2 mM a- thioglycerol (Sigma). The cell line was passaged every 3^4 d.
HMC-1 cells were grown with the addition of 0, 0.1, 1, or 10 mM of atRA
for 6 d and then the cell number and viability were determined by trypan
blue exclusion.
Flow cytometry analysis The expression of Kit was analyzed with
£ow cytometry, for which harvested cells were incubated on ice for
30 min with mouse antihuman Kit (Pharmingen, San Diego, CA),
washed, and incubated on ice for 30 min with phycoerythrin-conjugated
rabbit antimouse Fab02 fragments (Dakopatts). Fluorescence-activated cell
sorting analysis was performed with a FACSort (Becton Dickinson,
MountainView, CA).
Skin organ culture in the presence of atRA Healthy-looking skin
specimens were obtained in connection with mastectomies for breast
cancer from three female subjects after receiving consent. The skin
specimens were rinsed several times with D-PBS to remove residual blood
and the subcutaneous fat was released by using a knife. Punch biopsies
(6 mm) were taken from the specimens and were placed into the wells of
a six-well plate (four punch biopsies per well). Prewarmed medium (3 ml
of 10% fetal bovine serum containing Dulbecco’s modi¢ed Eagle’s
medium, 100 U per ml penicillin, and 100 mg per ml streptomycin) was
added into each well followed by atRA (Sigma) at a ¢nal concentration
of 0, 0.1, 1.0, or 10 mM. The skin biopsies were cultured submerged in the
medium at 371C and 5% CO2 for 2, 7, or 14 d (Kivinen et al, 2001). The
medium and atRAwere replaced every second or third day. At the end of
each culture period one skin biopsy was randomly chosen from each well.
The biopsy was embedded in OCT compound (Miles Scienti¢c,
Naperville, IL) and frozen in isopentane cooled with a mixture of
absolute ethanol and dry ice (Kivinen et al, 2001). Control (day 0) skin
biopsy was immediately embedded and frozen.
Treatment of normal human skin with RA cream Three healthy
subjects (two males, aged 37 and 41 y, and one female, aged 35 y) were
included in the study. All subjects gave informed consent. Three treatment
sites (each about 33 cm) on the nonsun-exposed healthy skin of the left
medial arm or forearm were chosen and marked.The ¢rst and control skin
area was treated with Novalans base cream (Orion, Helsinki, Finland)
once a day for 6 wk. The second skin area was treated ¢rst with
Novalans base cream for 4 wk and subsequently with 0.1% atRA
dissolved in Novalans cream for 2 wk. The third skin area was treated
with 0.1% atRA cream once a day for 6 wk. After the treatment, one 4
mm punch biopsy was taken from each skin area following local
anesthesia (1% lidocaine with epinephrine). Each specimen was
immediately embedded in OCT compound for preparing cryosections.
The methods were approved by the Ethics Committee of Kuopio
University Hospital, Kuopio, Finland.
Histochemical staining of skin sections Cryosections of 5 mm
thickness were cut on poly L-lysine coated slides, which were stored at
201C. Prior to staining, the sections were ¢xed in cold acetone for 10^15
min. Tryptase protein was stained with a rabbit polyclonal antibody (0.19
mg per ml) (Kivinen et al, 2001), chymase protein with a mouse
monoclonal antibody (0.1 mg per ml) (Biogenesis, Poole, U.K.), and
Kit protein with a mouse antihuman CD117/Kit monoclonal antibody
(3 mg per ml) (Southern Biotechnology, Birmingham, AL). The bound
antibodies on skin sections were visualized with the avidin^biotin
peroxidase technique using the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA) together with 0.05% 3,30 -diamino-
benzidine tetrahydrochloride, 0.04% nickel chloride, and 0.03% hydro-
gen peroxide. The staining was controlled by omitting the speci¢c anti-
bodies. Chymase activity was stained enzyme-histochemically by using
1mM Suc-Val-Pro-Phe-4-methoxy-2-naphthylamide (Bachem, Bubendorf,
Switzerland) as the substrate and 0.5 mg per ml Fast Black K salt (Sigma) as
the chromogen (Kivinen et al, 2001). Mast cells positive for tryptase and
chymase were counted in sequential sections. The cells were counted
immediately beneath the epidermis as indicated inTable I andTable II.
Tumor necrosis factor a (TNF-a) or Kit in mast cells was stained by
using the sequential double-staining method (Ackermann and Harvima,
1998; Kivinen et al, 2001). Brie£y, tryptase was ¢rst identi¢ed enzyme-
histochemically with 1 mM Z-Gly-Pro-Arg-4-methoxy-2-naphthylamide
(Bachem) and 0.5 mg per ml Fast Garnet GBC (Sigma); this was followed
by photographing, then removal of the red azo dye with Tween 20,
immunohistochemical staining with rabbit polyclonal antihuman TNF-a
antibody (50 mg per ml) (Sera-Laboratory, Crawley Down, U.K.) or mouse
antihuman CD117/Kit monoclonal antibody (3 mg per ml), and ¢nally re-
photographing at exactly the same site as the previous picture. By
comparing the micrographs the percentage of tryptase-positive mast cells
expressing TNF-a or Kit was calculated.
Statistical analysis For statistical analysis we used an analysis of variance
(ANOVA), followed by multiple comparison by Fisher’s method. An
asterisk denotes po0.05, two asterisks po0.01, and three asterisks po0.001.
Table I. The number of tryptase-, chymase-, and Kit-positive mast cells in the dermal skin during skin organ culture in the
presence of atRAa
Tryptase protein Chymase protein Chymase activity Kit protein
0 0.1 1.0 10 0 0.1 1.0 10 0 0.1 1.0 10 0 0.1 1.0 10
atRA (mM) atRA (mM) atRA (mM) atRA (mM)
Control 70730 5679 5077 59715
2 d 4277 4576 3877 48713 4876 45716 47712 47712 4074 4278 3777 4078 3076 32714 2978 3376
7 d 3174 3079 43714 3477 45712 4279 4679 4977 21710 1977 2279 2075 30715 2679 2476 2173
14 d 2878 40718 33714 26715 42710 5372 5278 5177 970 1473 871 1377 1776 2474 1978 2173
aThe results are expressed as mean7SD (cells per mm2) (three independent cultures). Tryptase, chymase, and Kit proteins were stained immunohistochemically and
chymase activity enzyme-histochemically. The cells were counted on three skin sections per specimen in an area of 1.2 mm (width) 0.6 mm (depth) immediately
beneath the epidermis.
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RESULTS
RA inhibits the SCF-dependent development of mast
cells from CBMNC To assess whether RA a¡ects the SCF-
dependent development of mast cells, and if the two isoforms
atRA and 9cisRA in£uence this process similarly, we examined
the e¡ect of RA on the di¡erentiation of human mast cells from
CBMNC cultured in suspension for 4 wk. The cells were
cultured in the presence of rhSCF at 50 ng per ml and atRA or
9cisRA at 0, 1, 10, 100, or 1000 nM. The total cell number in the
cultures was calculated and related to the control cultures without
RA (Fig 1a). The lower concentrations (1 and 10 nM) of atRA
and 9cisRA had no signi¢cant e¡ect on the total cell number,
but with 100 nM RA it was reduced to half of that with only
SCF, and 1000 nM RA had a pronounced negative e¡ect on the
cell number. This inhibitory e¡ect of RA on the cell number
could be observed already after 2 wk of culture (data not
shown).
The actual number of mast cells that had developed in the
cultures after 4 wk was determined using an antibody against
tryptase, a mast-cell-speci¢c serine proteinase. In the cultures
with SCF alone, 50% of the cells were tryptase positive.When
increasing amounts of atRA or 9cisRA were added to the
cultures the number of tryptase-positive mast cells was reduced
(Fig 1b). Based on these results we chose to use atRA for the
rest of this study.
We also performed a time course on the e¡ect of atRA (1 mM)
on total cell number and on mast cell development (Fig 2). The
total cell number was greatly diminished after 2 wk of culture in
the presence of SCFþ atRA compared to SCF alone (118103 vs
422103 cells). No mast cells could be detected when atRAwas
present. The viability was 4 85% in cultures treated with either
SCF or SCFþ atRA.
Mast cell development is inhibited in cultures pretreated
with RA, but not when RA exposure is delayed To be able
to clarify if RA is a¡ecting the SCF-dependent development of
mast cells at an early or late stage of di¡erentiation, we cultured
CBMNC using simultaneous addition of SCF and RA as well as
delayed addition of RA, and pretreatment with RA. The total
culture period was 6 wk. In the cultures with only SCF added,
the total cell number decreased to 30% of the input level
(Fig 3a), and 84% (250103 cells) of these cells were tryptase-
positive mast cells (Fig 3b, c). When RA was present for the
whole 6 wk (7SCF), very few cells could be detected at the end
of the culture period, consistent with the results in the 4 wk
cultures (Figs 1a, 3a).
To determine the sensitivity to RA of cells committed to the
mast cell lineage, we delayed the addition of RA to the SCF
cultures. The cells were grown for 2 wk in SCF before RAwas
included together with SCF for four more weeks. The total cell
Figure1. E¡ects of atRA and 9cisRA on CBMNC.The cells were cul-
tured in suspension for 4 wk in the presence of rhSCF at 50 ng per ml and
atRA or 9cisRA at 0 (control), 1, 10, 100, or 1000 nM. The results represent
the mean of cells from ¢ve donors (atRA) or three donors (9cisRA) cul-
tured in duplicate7SEM. Statistically signi¢cant di¡erences between SCF
alone and the other groups are indicated as follows: npo0.05, nnpo0.01,
nnnpo0.001. (A) Total number of cells expressed as percentage of control.
(B) Number of mast cells expressed as percentage of control.
Figure 2. Time course on the e¡ect of atRA on CBMNC. CBMNC
were cultured in the presence of SCF (50 ng per ml) (squares)7atRA
(1 mM) (circles) for 2, 4, or 6 wk. Open symbols represent total cell number
and ¢lled symbols mast cell number.The results represent the mean of cells
from ¢ve donors cultured in duplicate7SEM.
Table II. The number of tryptase- and chymase-positive
mast cells and the percentage of TNF-a-positive mast cells
in the dermal skin following treatment with topical 0.1%
atRA creama
Mast cell Control 2 weeks 6 weeks
staining skin atRA cream atRA cream
Tryptase protein (cells per mm2) 127711 153727 175728n
Chymase protein (cells per mm2) 121716 126711 12475
Chymase activity (cells per mm2) 74726 86713 73733
TNF-a (%) 39730 39720 29713
aThe results are expressed as mean7SD (n¼ 3). Tryptase and chymase proteins
were stained immunohistochemically and chymase activity enzyme-histochemi-
cally. TNF-a-positive mast cells were stained by using the sequential double-stain-
ing method. Tryptase- and chymase-positive cells were counted immediately
beneath the epidermis in an area of 2 mm (width) 0.6 mm (depth).
npo0.05 compared to control.
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number in cultures was somewhat (but not signi¢cantly) lower
than in the SCF-treated cultures (Fig 3a). Development of mast
cells was attenuated, yet as many as 57% (150103) of the cells
still were mast cells (Fig 3b, c).
We also wanted to ¢nd out if cells cultured in RA could
survive and di¡erentiate into mast cells when transferred to
SCF-containing medium. The cells were therefore cultured in
RA for 2 wk before replacement with SCF-containing medium
for 4 wk. This pretreatment with RA resulted in a low
proportion (9%) of mast cells (Fig 3c), indicating that the
number of progenitor cells capable of a di¡erentiation response
to SCF had diminished after 14 d of exposure to RA.
RAR/RXR as well as RXR/RXR dimers are involved in
the inhibition of mast cell development RA mediates its
signals via binding to the nuclear receptors RAR and RXR,
which function as RAR/RXR and RXR/RXR dimers. To
investigate the nuclear RA receptors involved in mast cell
development we used speci¢c agonists: the RAR agonist
TTNPB (TT), and the RXR agonist SR11237 (SR). CBMNC
were cultured for 4 wk with SCF7TT and/or SR. Both
agonists, used as single agents, reduced the total cell number
and showed an even greater e¡ect on mast cell development
(Fig 4ac). There was no signi¢cant di¡erence when the
agonists were combined, except for a further decrease in total
cell number compared toTT alone.
RA negatively a¡ects cell growth and expression of Kit on
HMC-1 cells We also determined the e¡ects of RA on the
human mast cell line HMC-1, which is used as an in vitro model
to study immature mast cells. HMC-1 cells were grown for 6 d in
the presence of 0, 0.1, 1, or 10 mM atRA. Thereafter cell growth
and Kit expression were analyzed. RA was found to
signi¢cantly inhibit the growth of HMC-1 cells at 0.1 mM
(Fig 5a). At the highest concentration used, 10 mM, the cell
growth was inhibited by more than 40%. RA did not a¡ect the
viability of the cells (data not shown). RA also a¡ected the
expression of Kit. At 1 mM, there was a 45% reduction of Kit
surface expression compared to untreated cells (Fig 5b).
RA has no e¡ect on the number of mast cells and Kit-
positive cells during skin organ culture Based on the strong
inhibitory e¡ect of RA on mast cell development and Kit
expression we next investigated the e¡ects of RA on mature
mast cells in the skin tissue during skin organ culture. As shown
in Table I, the number of tryptase-, chymase- and Kit-positive
cells decreased steadily during cultivation. It is likely that this
decrease in mast cell numbers re£ects a rapid induction of mast
cell apoptosis caused by the destruction of skin specimens
in prolonged cultures (Kivinen et al, 2002). The rate of
disappearance of tryptase-positive cells was higher than that of
cells with chymase immunoreactivity, suggesting better
solubilization of tryptase from the site of release to the medium.
The rapid decrease in the number of mast cells with chymase
activity probably re£ects chymase exposure to and inactivation
Figure 3. E¡ects of delayed addition of or pretreatment with atRA
on CBMNC. Cells were cultured in suspension under the following con-
ditions: (1) 6 wk in rhSCF (50 ng per ml); (2) 6 wk in atRA (1000 nM); (3)
6 wk in SCF + RA; (4) 2 wk in SCF and then 4 wk in SCF+RA; (5) 2 wk
in RA and then 4 wk in SCF. The results represent the mean of cells from
¢ve donors cultured in duplicate7SEM. Statistically signi¢cant di¡erences
between SCF alone and the other groups are indicated as follows: npo0.05,
nnpo0.01, nnnpo0.001. (A) Total number of cells. (B) Number of mast
cells. (C) Percentage of mast cells.
Figure 4. E¡ects of RAR and RXR agonists on CBMNC. The cells
were cultured in suspension for 4 wk in the presence of rhSCF (50 ng per
ml) with either no additives, TTNPB (100 nM), SR11237 (1000 nM), or
both TTNPB and SR11237. The results represent the mean of cells from
two donors cultured in duplicate7SEM. Statistically signi¢cant di¡er-
ences between SCF alone and the other groups are indicated as follows:
npo0.05, nnpo0.01, nnnpo0.001. (A) Total number of cells. (B) Number
of mast cells. (C) Percentage of mast cells.
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by serum protease inhibitors (Kivinen et al, 2001). Nevertheless,
no marked e¡ects were observed of exogenous 0.1, 1.0, or 10 mM
atRA on the number of tryptase-, chymase- and Kit-positive
cells. At every concentration of atRA the cell number decreased
steadily and identically during culture. As a control we cultured
skin specimens in the presence of up to 200 ng per ml SCF. This
treatment resulted in a signi¢cant decrease in the number of Kit-
positive cells within 2 d of culture (Kivinen et al, 2002). This
indicates that the mast cells were responsive in the skin
specimens to exogenous agents. Therefore, the result suggests
that RA neither decreased the number of mature mast cells nor
a¡ected the expression of Kit in these cells.
Topical treatment of normal skin with RA cream increases
the number of tryptase-positive cells but has no e¡ect on
chymase-positive cells or Kit or TNF-a expression To
further clarify the e¡ect of RA on normal cutaneous mast cells
we next investigated the e¡ects of atRA on mast cell numbers
in vivo. Thin and nonsun-exposed normal skin of three healthy
volunteers was treated with 0.1% atRA cream for 0, 2, and 6
wk. The concentration of atRA in the cream was 3.3 mM, i.e.,
about 1000-fold higher than the atRA concentration in skin
organ culture. Thus, only 0.1%^1% of the atRA in the cream
absorbed into the upper dermis should be su⁄cient to produce
an e¡ect on mast cells. In agreement with this, in each subject
retinoid dermatitis developed, ranging from slight erythema to
scaly and psoriasiform plaque by 6 wk. The number of tryptase-
positive mast cells in the upper dermis increased gradually during
atRA treatment (Fig 6a, c, and Table II); meanwhile no
alterations in the number of mast cells with chymase
immunoreactivity or chymase activity were found (Table II).
Owing to the development of retinoid dermatitis and the fact
that TNF-a is a marked proin£ammatory cytokine in mast cells,
the percentage of TNF-a-positive mast cells was determined but
no marked changes were observed during atRA treatment.
Therefore, the results suggest that the number of tryptase-
positive, chymase-negative (MCT) type of mast cell increases
during atRA treatment whereas the major cutaneous mast cell
type (MCTC) remains una¡ected.
Staining for Kit on tryptase-positive cells showed that all mast
cells in control specimens expressed Kit (Fig 6b). No alterations
in Kit staining on mast cells were observed during atRA
treatment, and all tryptase-positive cells were positive for Kit
after 2 and 6 wk (Fig 6d).
Figure 5. E¡ects of RA on HMC-1 cells. (A) Cell growth. Cells were
cultured in suspension for 6 d in the presence of 0 (control), 0.1, 1, or 10 mM
atRA. The results are presented as percentage of the number of cells in
control cultures, and represent the means of three independent experiments
cultured in duplicate,7SEM. npo0.05, nnpo0.01, nnnpo0.001. (B) Kit ex-
pression. Cells were cultured in duplicate for 6 d in the absence or presence
of 1 mM atRA. The cells were stained with £uorescent antibodies against
Kit and analyzed on a £ow cytometer. The ¢lled area represents cultures
without RA and the bold line cultures with RA. The histogram shows
one representative experiment of three independent ones.
Figure 6. Histochemical staining of skin sections. Human skin was
treated for 6 wk with either Novalan base cream (A, B) or Novalan base
cream containing 0.1% atRA (C, D). Tryptase was stained enzyme-histo-
chemically to identify mast cells (A, C) followed by immunohistochemical
staining of the same skin sections for Kit (B, D). All tryptase-positive mast
cells exhibit immunopositivity of Kit in control and RA-treated skin.
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DISCUSSION
In this study we have investigated the e¡ects of retinoids on mast
cell development in vitro and in vivo.We found that RA reduced
the total cell number in SCF-supplemented CBMNC cultures
and also the number of tryptase-positive mast cells in these cul-
tures. This could be due to a direct inhibitory e¡ect of RA on
hematopoietic progenitor cells as has been demonstrated in
humans and mice (Bradley et al, 1983; Jacobsen et al, 1994; Purton
et al, 1999), although we cannot exclude the possibility of an in-
direct e¡ect. In contrast to the strong inhibitory e¡ect of RA on
mast cell development in vitro, no obvious e¡ect could be deter-
mined on mature cutaneous mast cells in organ cultures either in
vitro or in vivo.
Our results suggest that the e¡ect of RA is mainly on mast cell
progenitors. When the addition of RA was delayed for 2 wk, a
substantial number of mast cells developed in SCF-supplemented
medium, although signi¢cantly fewer compared to control cul-
tures with no addition of RA. Thus, mast cell progenitors that
have matured in vitro appear to be more resistant to the e¡ects of
RA than uncommitted progenitors and early mast cell progenitors.
In the experimental setting where we investigated whether
progenitors can survive in RA and di¡erentiate when transferred
to SCF-containing medium, the total cell number was not signif-
icantly di¡erent from the SCF-treated control cells. Only a low
proportion of the cells had di¡erentiated into mast cells, however.
We have earlier described that progenitors can survive for at least
3 wk in culture medium in the absence of SCF, and then develop
into mast cells when SCF is added (Hjertson et al, 1999). In that
study we found that approximately 50  103 mast cells devel-
oped and that they constituted 30% of the total cells. These num-
bers are higher than when cells were cultured in the presence of
RA for the ¢rst 2 wk (Fig 3). These results point to a negative
e¡ect of RA on mast cell development, and a less pronounced
inhibitory e¡ect on other cell lineages. Indeed there are reports
that RA supports granulocytic di¡erentiation but suppresses ery-
throid development (Gratas et al, 1993). In a study by Tsai et al
(1992) a mutated dominant-negative RARwas shown to induce
a switch in the FDCP mix cell line from spontaneous neutrophil/
monocyte di¡erentiation into basophil/mast cell development.
The AML14 leukemic cell line, which can di¡erentiate into eosi-
nophils, is induced by RA to neutrophil di¡erentiation (Paul et al,
1995). Furthermore, RA inhibits the development of eosinophils
and basophils, but not neutrophils and macrophages, from
human bone marrow or cord blood (Upham et al, 2002). Taken
together, these results suggest that RA promotes the di¡erentia-
tion of neutrophils and monocytes whereas the development of
erythrocytes, eosinophils, basophils, and mast cells is suppressed.
Kinoshita et al (2000) have earlier reported that RA is a nega-
tive regulator of human mast cell di¡erentiation in vitro. In con-
trast to our ¢ndings they found that early steps in mast cell
development were less sensitive to RA compared to 10-wk-old
in vitro developed mast cells. One explanation for this discrepancy
between the studies could be that, whereas we used the mono-
nuclear cell population of cord blood cells cultured in 10% ser-
um, they used puri¢ed CD34þ cells cultured in serum-free
medium. Both these systems have their advantages and disadvan-
tages. The advantage with enriched cell populations cultured in
serum-free medium is that it enables one to study the e¡ect of
single factors on a de¢ned cell population. Although it is di⁄cult
to exclude indirect e¡ects of RA on mast cell development using
a mononuclear cell population, we believe it is more physiologic
to culture not only CD34þ cells but also other mononuclear
cells in the presence of serum factors, as that should be a better
representation of the in vivo situation. Furthermore, in this study
in addition to analyzing the e¡ect of RA on the in vitro develop-
ment of mast cells, we also analyzed the e¡ect of RA on the
HMC-1 cell line, mast cells in skin plants, and mast cells in nor-
mal skin. The results achieved from these four di¡erent mast cell
systems all pointed to an e¡ect of RA on mast cell progenitors
and not on mature mast cells.
We also compared the e¡ects of atRA with another naturally
occurring isoform, 9cisRA. 9cisRA binds to both RAR and
RXR (Heyman et al, 1992), whereas atRA binds only to RAR
(Giguere et al, 1987; Heyman et al, 1992). Similarly to atRA, 9cis-
RAwas found to inhibit the development of mast cells, although
atRA had an e¡ect at 1 nM, whereas a signi¢cant e¡ect with 9cis-
RAwas obtained at 10 nM. In agreement with our ¢ndings, there
are other reports of atRA and 9cisRA having similar e¡ects in a
given system (Jacobsen et al, 1994; Fahlman et al, 1995). This is not
surprising as atRA partly isomerizes to 9cisRA in cell culture
(Heyman et al, 1992).
The concentration of atRA used in this study, 1 mM, has fre-
quently been used in in vitro studies (Gratas et al, 1993; Fahlman
et al, 1995; Purton et al, 1999), and can be achieved in tissue under
therapeutic conditions (Lucek and Colburn, 1985). The inhibitory
e¡ect of RA seen on mast cell development is not likely to be
due to toxic e¡ects, as the toxic level of RA for mast cells has
been reported to be 100-fold higher (Eichelberg and Schmutzler,
1988). Although we did not speci¢cally examine the number of
apoptotic cells in this study, we did not observe any di¡erence in
cell viability assessed by trypan blue exclusion. Furthermore,
treatment of HMC-1 cells with 10 mMRA did not a¡ect the via-
bility (data not shown), and it has recently been reported that
RA does not a¡ect the survival of 10-wk-old in vitro developed
mast cells (Kinoshita et al, 2000). Thus, RA appears not to a¡ect
mast cell survival.
We also included the human mast cell line HMC-1, represent-
ing an immature mast cell type (Nilsson et al, 1994a), in this study.
RA signi¢cantly reduced the cell growth of HMC-1 cells. The
e¡ect was not so profound as on CBMNC, however, even
though a higher concentration (10 mM) was used. This is in line
with our results that RA has less e¡ect on cells committed to the
mast cell lineage. The £ow cytometry analysis showed that RA
downregulates the expression of Kit on HMC-1 cells. As Kit is
the receptor for SCF, the main growth and di¡erentiation factor
for mast cells, this downregulation of Kit might explain the RA-
mediated suppression of cell growth in HMC-1 cells as well as
the inhibition of development of mast cells from CBMNC.
Although we have not investigated the mechanisms by which
RA inhibits mast cell development, one could speculate that it is
through growth inhibition of mast cell progenitors. RA inhibits
the cell growth of both CBMNC and HMC-1 (this study), as
well as cord-blood-derived mast cells (Kinoshita et al, 2000). It
has been described that RA regulates the transcription of genes
involved in cell cycle regulation, e.g., p21 (Liu et al, 1996). Thus,
RA might a¡ect mast cell di¡erentiation through regulation of
the cell cycle, although this e¡ect remains to be de¢ned.
Cultivation of whole skin specimens has been used in in vitro
studies to examine changes in skin tissue under controlled condi-
tions. There are limitations in this complex culture model, how-
ever, as the optimal conditions for di¡erent cell types, including
mast cells, are not well known and they may vary from cell to
cell. Also, the tissue specimen does not have blood circulation
and neural control. The addition of SCF to the culture medium,
however, resulted in a clear and signi¢cant decrease in the num-
ber of Kit-positive cells within 2 d, possibly due to proteolytic
shedding, downregulation, or internalization and degradation of
Kit (Kivinen et al, 2002). These results indicate that mast cells are
responsive in the culture conditions used. In contrast to this e¡ect
of SCF, RA at up to 10 mM concentration had no apparent e¡ect
on the number of mast cells and Kit-positive cells in skin organ
culture. As cutaneous mast cells are predominantly mature
MCTC, the result obtained again supports the conclusion that
RA does not a¡ect more committed and mature mast cells in
tissue. Furthermore, this conclusion is in line with the result
that topical RA treatment of normal skin had no e¡ect on the
number of chymase-positive MCTC and on the expression of
TNF-a and Kit in mast cells. The increase in the number
of MCT during RA treatment probably re£ects the development
of retinoid dermatitis. By comparison, MCT have been detected
in the skin of eczema patients (JUrvikallio et al, 1997). Also, RA
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could directly have a¡ected mast cells or mast cell precursors
entering the tissue. Although retinoid dermatitis is a common
feature of topical RA treatment and up to 0.1% RA concentra-
tion has been used in topical preparations, it is possible to reduce
the development of retinoid dermatitis by using lower RA con-
centrations.Whether a lower concentration of RA might produce
a di¡erent result on mast cells is not known. The retinoid derma-
titis developed in this study, however, ranged from slight erythe-
ma to psoriasiform plaque. Regardless of this variation in clinical
outcome, the changes in mast cells appeared to be consistent and
steady in these three subjects.
The results presented in this study suggest that RA suppresses
commitment of progenitor cells into the mast cell lineage and/or
acts on early mast cell progenitors, whereas mature mast cells or
mature cutaneous mast cells are less susceptible to RA.
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